The 2020 expert consensus by the Neuroophthalmology Group of the Chinese Medical Association outlines the clinical use of Compound Anisodine Injection for ischemic eye diseases, which can cause irreversible vision loss if untreated. The consensus highlights the drug's promising efficacy but stresses the need for standardized application due to varied practitioner usage. It categorizes ischemic eye diseases and details the drug's application in conditions like non-arteritic anterior ischemic optic neuropathy and diabetic retinopathy. Recommendations include early treatment, proper dosing, and potential combination therapies. The document underscores the importance of timely intervention, monitoring, and safety guidelines to enhance treatment efficacy and patient safety.